Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Laboratoire HRA Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011798
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Laboratoire HRA Pharma (HRA Pharma) is a healthcare products provider that offers women’s health and endocrinology products. The company offers a wide range of women’s health products which include emergency contraception, uterine fibroids, regular contraception and genital herp products among others. Its endocrinology products comprise advanced adrenal cortical carcinoma and cushing’s syndrome medicines; and lysosafe service devices. The company operates through partnerships with pharmaceutical companies, public and private institutions, healthcare professionals and others. It operates in France, Germany, Ireland, Italy, Switzerland, Spain, Portugal, Belgium and the UK. HRA Pharma is headquartered in Paris, France.

Laboratoire HRA Pharma SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Laboratoire HRA Pharma SAS, Medical Devices Deals, 2011 to YTD 2017 9
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
HRA Pharma Acquires Compeed from Cilag 11
HRA Pharma Acquires Ovarian Cancer Immunotherapy from Pantarhei Bioscience 12
Venture Financing 13
Embera NeuroTherapeutics Raises USD1.9 Million in Series A-2 Financing 13
Private Equity 14
Astorg Asset Management and Goldman Sachs Acquire Laboratoire HRA Pharma 14
Riverside Acquires Minority Stake in HRA Pharma 16
Partnerships 17
HRA Pharma Enters into Distribution Agreement with Laboratoires Carilene 17
Licensing Agreements 18
ASKA Pharma Enters into Licensing Agreement with HRA Pharma 18
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 19
Gedeon Richter Expands Licensing Agreement With HRA Pharma 20
ASKA Pharma Enters Into Licensing Agreement With HRA Pharma For ellaOne 21
Asset Transactions 22
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 22
Laboratoire HRA Pharma SAS – Key Competitors 23
Laboratoire HRA Pharma SAS – Key Employees 24
Laboratoire HRA Pharma SAS – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Corporate Communications 27
Jul 12, 2016: HRA Pharma Announces CEO Transition to Position Company for the Next Phase of Growth 27
Product News 28
11/21/2016: FIBRISTAL, The First And Only Medication Indicated For Uterine Fibroids, Receives Approval From Health Canada For Long Term Intermittent Treatment 28
01/20/2016: Depression experts question effectiveness of stress hormone drug 29
Clinical Trials 31
Jan 17, 2017: Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids 31
Oct 17, 2016: Allergan to Present New Data Including Ulipristal Acetate at the American Society of Reproductive Medicine (ASRM) Scientific Congress and Expo in Salt Lake City 33
May 09, 2016: Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Key Facts 2
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Laboratoire HRA Pharma SAS, Deals By Therapy Area, 2011 to YTD 2017 8
Laboratoire HRA Pharma SAS, Medical Devices Deals, 2011 to YTD 2017 9
Laboratoire HRA Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
HRA Pharma Acquires Compeed from Cilag 11
HRA Pharma Acquires Ovarian Cancer Immunotherapy from Pantarhei Bioscience 12
Embera NeuroTherapeutics Raises USD1.9 Million in Series A-2 Financing 13
Astorg Asset Management and Goldman Sachs Acquire Laboratoire HRA Pharma 14
Riverside Acquires Minority Stake in HRA Pharma 16
HRA Pharma Enters into Distribution Agreement with Laboratoires Carilene 17
ASKA Pharma Enters into Licensing Agreement with HRA Pharma 18
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 19
Gedeon Richter Expands Licensing Agreement With HRA Pharma 20
ASKA Pharma Enters Into Licensing Agreement With HRA Pharma For ellaOne 21
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 22
Laboratoire HRA Pharma SAS, Key Competitors 23
Laboratoire HRA Pharma SAS, Key Employees 24
Laboratoire HRA Pharma SAS, Other Locations 25
Laboratoire HRA Pharma SAS, Subsidiaries 25

★海外企業調査レポート[Laboratoire HRA Pharma SAS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Polychem Limited (506605):企業概要、財務及び戦略的SWOT分析
    Summary Polychem Limited (Polychem) is a chemical company. The company manufactures styrene, polystyrene, vinyl acetate and polyvinyl alcohol. It manufactures polymers and co-polymers, divinyl benzene, acrylic acid and acrylates through suspension polymerization route or emulsion polymerization rout …
  • Nanosonics Ltd (NAN)-医療機器分野:企業M&A・提携分析
    Summary Nanosonics Ltd (Nanosonics) is a medical technology company, which focuses on the development of technologies for infection control. Its product portfolio includes decontamination products and accessories for the prevention of hospital acquired infections (HAI). The company’s trophon EPR is …
  • BYD Company Limited (002594):企業のM&A・提携動向(エネルギー分野)
    Summary BYD Company Limited (BYD) designs, manufactures and sells rechargeable batteries, photovoltaic products, handset components, and other electronic products. It also offers whole product assembly services to clients. As part of its automobile business, the company manufactures and offers tradi …
  • CardioMEMS, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' CardioMEMS, Inc. Mergers and Ac …
  • Grupe SAB de CV:企業の戦略・SWOT・財務分析
    SummaryGrupe SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Finding …
  • O2 Czech Republic a.s. (TELEC):企業財務及び戦略的SWOT分析
    Summary O2 Czech Republic a.s. (O2), a subsidiary of Telefonica, S.A. is a telecommunication service provider that operates mobile and accesses. The company provides internet, fixed access and IPTV, and mobile services to its customers. It offers telecommunication services, wholesale services, netwo …
  • RGC Resources, Inc. (RGCO):企業財務及び戦略的SWOT分析
    Summary RGC Resources, Inc. (RGC Resources) is an energy services company that distributes and sells natural gas to residential, commercial and industrial customers. The company provides home appliances such as gas furnaces, natural gas water heaters, gas dryers and ranges, gas logs and space heater …
  • AnaptysBio, Inc.(製薬・医療分野):企業M&A動向
    Summary AnaptysBio, Inc. (AnaptysBio) is a biotechnology company. The company develops therapeutic antibody products. It uses somatic hypermutation for antibody discovery and optimization. AnaptysBio develops a pipeline of therapeutic antibody candidates, which include differentiated programs in can …
  • Carmot Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Carmot Therapeutics Inc (Carmot Therapeutics) is a biotechnology company which discovers and develops drugs for the treatment of cancer, inflammation and metabolic diseases. The company’s product portfolio encompasses investigational candidates in preclinical trials: peptide-small molecule h …
  • DiscGenics, Inc.:企業のM&A・提携動向(医療機器分野)
    Summary DiscGenics, Inc. (DiscGenics) is a biotechnology company that develops advanced spinal therapeutics. The company develops therapies to treat patients with diseases of the intervertebral disc. Its product portfolio include two products namely, Injectable Discogenic Cell Therapy (IDCT), develo …
  • Eloro Resources Ltd. (ELO):企業財務及び戦略的SWOT分析
    Summary Eloro Resources Ltd. (Eloro Resources) is an energy company that offers mineral exploration services. The company acquires, explores and develops precious and base-metal resources in Quebec. It explores for silver, titanium, gold, iron, copper, vanadium, manganese, barium and strontium, amon …
  • Advanced Systems Automation Limited (5TY):企業の財務及び戦略的SWOT分析
    Summary Advanced Systems Automation Limited (ASAL) a subsidiary of ASTI Holdings Limited is a manufacturing company that manufactures automated backend equipment for semiconductors. The company offers products and services through categories such as align and attach, encapsulation, singulation and s …
  • Gulfsands Petroleum plc (GPX):企業のM&A・提携動向(石油・ガス分野)
    Summary Gulfsands Petroleum plc (Gulfsands) is an oil and gas company that offers exploration services. The company explores, exploits, develops and produces oil and natural gas. It has interests in oil exploration and development projects in the Syrian Arab Republic. Gulfsands operates projects inc …
  • Temenos Group AG : Technology and Communications:企業概要及びSWOT/財務分析
    Summary ICD Research's "Temenos Group AG : Technology and Communications - Company Profile, SWOT and Financial Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, busine …
  • Pelita Holdings Sdn. Bhd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Pelita Holdings Sdn. Bhd. Merge …
  • Viriom Inc-製薬・医療分野:企業M&A・提携分析
    Summary Viriom Inc (Viriom) focuses on the development of antivirals for HIV treatment and prevention. The company’s lead pipeline product candidate Elpida, is a bioavailable prodrug, and VM-1500A, a non-nucleoside HIV reverse transcriptase inhibitor. Its partner portfolio includes Roche, ChemDiv, I …
  • Oneok, Inc. (OKE)(石油・ガス分野):企業M&A動向
    Summary ONEOK, Inc. (ONEOK) is a diversified energy company. The company’s products include natural gas and natural gas liquids. Its businesses include natural gas gathering and processing; natural gas pipelines; natural gas liquids such as gathering, fractionation and storage; and pipelines and dis …
  • ACADIA Pharmaceuticals, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' ACADIA Pharmaceuticals, Inc. Me …
  • GREENoneTEc Solarindustrie GmbH:企業の戦略的SWOT分析
    GREENoneTEc Solarindustrie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Multan Electric Power Company:発電所・企業SWOT分析
    Multan Electric Power Company – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆